Purple Biotech Stock Quote PPBT - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.369799

Bid

0.35

Ask

0.3698

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

0.369799

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

25,237,922

Dividend Yield

PE Ratio

Earnings Per Share (EPS)

Revenue

Net Profit

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24. Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Sector

Pharmaceutical Preparations

Industry

Arrange Trans-freight, Cargo

Website

www.purple-biotech.com

Headquarters

Rehovot, Center, Isr

Founded

2013

Purple Biotech Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PPBT. The last closing price for Purple Biotech was $0.37. Over the last year, Purple Biotech shares have traded in a share price range of $ 0.00 to $ 0.00.

Purple Biotech currently has 25,237,922 shares outstanding.

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAGRAfrican Agriculture Holdings Inc	$ 0.201 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 61.42 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.32 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.44 (0.00%)	0
AACGATA Creativity Global	$ 0.8248 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.201 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 61.42 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.32 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.44 (0.00%)	0
AACGATA Creativity Global	$ 0.8248 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.201 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 61.42 (0.00%)	0
AADIAadi Bioscience Inc	$ 1.32 (0.00%)	0
AACIArmada Acquisition Corporation I	$ 11.44 (0.00%)	0
AACGATA Creativity Global	$ 0.8248 (0.00%)	0